rewirebio.iobenchmarks
Configuration

Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)

Windowed protection score (WPS), open chromatin regions, SVM: Feature setting: open chromatin regions.

6 evaluations · 33 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Model Capabilities & Hardware Requirements

Deployment facts recorded for Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024). Fields the record does not carry are marked not recorded.

ParametersNot recorded
Minimum VRAMNot recorded
Inference LatencyNot recorded
Context WindowNot recorded
AccessNot recorded
LicenseNot recorded

Evaluations and results

6 evaluations · 33 results. Different protocols are not a single leaderboard.

Sorted by AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationProtocol and datasetAUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (liver cancer vs controls; mean of 10 x 10-fold cross-validation)AUROC (liver cancer vs healthy; independent validation)AUROC (lung cancer vs healthy; independent validation)AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (lung cancer vs non-cancer; independent validation)AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (liver cancer vs healthy; independent validation)Sensitivity at 85% specificity (lung cancer vs healthy; independent validation)Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (lung cancer vs non-cancer; independent validation)Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (liver cancer vs healthy; independent validation)Sensitivity at 95% specificity (lung cancer vs healthy; independent validation)Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (lung cancer vs non-cancer; independent validation)Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2), DELFI 2019 internally cross-validated cancer detection cohort0.966 (best in column)0.9680.9850.980.961Not reportedNot reportedNot reported0.998Not reported10.8410.9330.9220.9150.907Not reportedNot reported0.995Not reported10.7190.8840.830.860.833Not reportedNot reported0.97Not reported0.9930.622
Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 pan-cancer vs healthy, Cristiano cohort, 10 x 10-fold cross-validation (Table 1 AUC), DELFI 2019 internally cross-validated cancer detection cohort0.966 (best in column)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported
Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2), Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reported0.954Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported
Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3), Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.75Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.512Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.271Not reportedNot reported
Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Mathios et al. independent lung cohort (Table S3), Mathios et al. 2021 independent lung cohort, 46 lung cancer and 385 healthy (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.856Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.717Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.5Not reportedNot reportedNot reportedNot reported
Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3), Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reported0.875Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.875Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.125Not reportedNot reportedNot reportedNot reportedNot reported
All 33 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.968 AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9560 to 0.9791

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C21; group 'BRCA'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.933 Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9117 to 0.9543

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E21; group 'BRCA'; row 'WPS'; column 'Sensitivity @85% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.884 Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8524 to 0.9149

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D21; group 'BRCA'; row 'WPS'; column 'Sensitivity @95% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.985 AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9794 to 0.9912

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C31; group 'CHOL'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.922 Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8852 to 0.9582

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E31; group 'CHOL'; row 'WPS'; column 'Sensitivity @85% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.83 Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7813 to 0.8787

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D31; group 'CHOL'; row 'WPS'; column 'Sensitivity @95% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.98 AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9732 to 0.9875

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C41; group 'CRC'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.915 Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8822 to 0.9478

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E41; group 'CRC'; row 'WPS'; column 'Sensitivity @85% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.86 Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8195 to 0.9005

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D41; group 'CRC'; row 'WPS'; column 'Sensitivity @95% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2)
Dataset: Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024)
0.954 AUROC (liver cancer vs controls; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9442 to 0.9639

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Jiang cohort liver cancer cross-validation

ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C91; group 'LIHC'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.998 AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9967 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C61; group 'NSCLC'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.995 Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9852 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E61; group 'NSCLC'; row 'WPS'; column 'Sensitivity @85% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.97 Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9396 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D61; group 'NSCLC'; row 'WPS'; column 'Sensitivity @95% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
1 AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9992 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C71; group 'OV'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
1 Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 1.0000 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E71; group 'OV'; row 'WPS'; column 'Sensitivity @85% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.993 Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9842 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D71; group 'OV'; row 'WPS'; column 'Sensitivity @95% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.841 AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.8124 to 0.8703

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C81; group 'PAAD'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.719 Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.6760 to 0.7624

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E81; group 'PAAD'; row 'WPS'; column 'Sensitivity @85% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.622 Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.5685 to 0.6749

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D81; group 'PAAD'; row 'WPS'; column 'Sensitivity @95% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.966 AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9598 to 0.9719

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C11; group 'PANCAN'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.961 AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9434 to 0.9793

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C51; group 'STAD'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.907 Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8693 to 0.9440

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E51; group 'STAD'; row 'WPS'; column 'Sensitivity @85% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.833 Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7842 to 0.8824

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D51; group 'STAD'; row 'WPS'; column 'Sensitivity @95% specificity'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)
0.75 AUROC (lung cancer vs non-cancer; independent validation)
unitless · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)

ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C21; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'WPS'; column 'AUC'
Configuration: Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)
0.512 Sensitivity at 85% specificity (lung cancer vs non-cancer; independent validation)
fraction · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

WPS (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)

ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E21; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'WPS'; column 'Sensitivity @85% specificity'

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Use this configuration

How it works, versions and access

Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ctdnafrag-20261009-config-hou2024-wps-open-chromatin.

Source locator: Article Table 1 row 'WPS', column 'open chromatin region'; Experimental Section P29-P41

Related records

How to cite

Windowed protection score (WPS), open chromatin regions, SVM (Hou et al. 2024). Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/ctdnafrag-20261009-config-hou2024-wps-open-chromatin/

Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.

The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence

Suggest a correction